fludarabine has been researched along with oblimersen in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bociek, RG; Boyd, TE; Chanan-Khan, AA; Koziner, B; Larratt, LM; Moore, JO; O'Brien, S; Pavletic, S; Rai, KR; Seymour, JF; Skotnicki, A | 1 |
| Boyd, TE; Chanan-Khan, AA; Gribben, J; Itri, LM; Koziner, B; Larratt, LM; Moore, JO; O'Brien, S; Rai, KR; Seymour, JF; Skotnicki, AB | 1 |
| Hallek, M | 1 |
| Bai, LY; Byrd, JC; Chan, KK; Cheney, C; Herman, SE; Jarjoura, D; Jin, Y; Lee, LJ; Lee, RJ; Mao, Y; Marcucci, G; Mo, X; Muthusamy, N; Ramanunni, A; Wang, X; Yu, B | 1 |
1 review(s) available for fludarabine and oblimersen
| Article | Year |
|---|---|
State-of-the-art treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Combined Modality Therapy; Cytostatic Agents; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Rituximab; Salvage Therapy; Thionucleotides; Transplantation, Homologous; Vidarabine | 2009 |
2 trial(s) available for fludarabine and oblimersen
| Article | Year |
|---|---|
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up Studies; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotides, Antisense; Proportional Hazards Models; Recurrence; Thionucleotides; Time Factors; Treatment Failure; Treatment Outcome; Vidarabine | 2007 |
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Thionucleotides; Vidarabine | 2009 |
1 other study(ies) available for fludarabine and oblimersen
| Article | Year |
|---|---|
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cell Line, Tumor; CpG Islands; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Gene Silencing; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Nanoparticles; Neoplasm Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Rituximab; RNA, Small Interfering; Thionucleotides; Toll-Like Receptor 9; Vidarabine; Xenograft Model Antitumor Assays | 2013 |